SPECTRUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1987-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.sppirx.com
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 34
- Registration Number
- NCT01741155
- Locations
- 🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸Virginia Cancer Institute, Richmond, Virginia, United States
🇺🇸Oncology Hematology Care Inc., Cincinnati, Ohio, United States
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
- Conditions
- Neutropenia
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 148
- Registration Number
- NCT01724866
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Los Angeles, California, United States
🇺🇸Beaver Medical Group, Highland, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 1
- Registration Number
- NCT01662102
- Locations
- 🇺🇸
Charleston Area Medical Center, Charleston, West Virginia, United States
🇺🇸Park Nicollet Institute, Saint Louis Park, Minnesota, United States
🇺🇸Northeast Georgia Cancer Care, Athens, Georgia, United States
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 18
- Registration Number
- NCT01587144
- Locations
- 🇮🇳
Bhagwan Mahaveer Cancer Hospital & Reseach Centre, Jaipur, Rajasthan, India
🇮🇳Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India
🇮🇳Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb
- Conditions
- SafetyPhosphate Binding Capacity
- Interventions
- Drug: Renazorb 3000 mg/dayDrug: Renazorb 6000 mg/dayDrug: Renazorb 1500 mg/dayDrug: Renazorb 4500 mg/day
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 32
- Registration Number
- NCT01560884
- Locations
- 🇺🇸
PAREXEL International - Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 5
- Registration Number
- NCT01549886
- Locations
- 🇺🇸
Oncology Specialists, Park Ridge, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Hackensack Medical Center, Hackensack, New Jersey, United States
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
- Conditions
- Diffuse Large B-cell LymphomaFollicle Center Lymphoma
- Interventions
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 79
- Registration Number
- NCT01510184
- Locations
- 🇺🇸
Hackensack UMC / John Theurer Cancer Center, Hackensack, New Jersey, United States
🇫🇷CHU Dupuytren, Limoges, Cedex, France
🇮🇱Chaim Sheba Medical Center, Tel-Hashomer, Israel
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 47
- Registration Number
- NCT01469221
- Locations
- 🇵🇱
Centrum Medycznego Kształcenia Podyplomowego, Samodzielny Publiczny Szpital Kliniczny im. Prof. W. Orłowskiego, Warszawa, Poland
🇵🇱Niepubliczny Zakład Opieki Zdrowotnej-Centrum Medyczne Szpital Świętej Rodziny sp z o.o., Łódź, Poland
🇸🇰Univerzitná nemocnica L. Pasteura Košice Univerzitná nemocnica L. Pasteura Košice, Košice, Slovakia
Zevalin Post-marketing Surveillance in Japan
- Conditions
- Non-Hodgkin's Lymphoma (NHL)
- Interventions
- Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 400
- Registration Number
- NCT01448928
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01439347
- Locations
- 🇺🇸
Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States